Infliximab Biosimilar 3
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Infliximab Biosimilar 3, covering 2025-06-04 to 2025-06-04. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis